525 Rec'd PCI/PTC 28 JUN 2002



Docket No.: 217860US0XPCT

ASSISTANT. COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RE: Application Serial No.: 10/030,271

Applicants: Toshio OTA, et al. Filing Date: January 8, 2002

For: APOPTOSIS-ASSOCIATED FACTOR

OBLON SPIVAK **McClelland** MAIER NEUSTADT P.C.

ATTORNEYS AT LAW

SIR:

Attached hereto for filing are the following papers:

Combined Declaration, Petition and Power of Attorney (7 pp. Executed); Filing of Declaration Under 37 CFR 1.53(f); Return Copy - Notification of Missing Requirments Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); Sequence Listing Paper (10 pp.); Sequence Listing Computer Readable Form (CRF) Diskette; Preliminary Amendment and Statement w/Marked-Up Copy (3 pp.); Declaration of Yuri Hio (1 page); Additional Claim Fees Due and Enclosed - \$84.00

Our check in the amount of \$84.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

07/03/E002 MKAYPAGH 00000103 10030271

01 FC#S64

84.00 OP

Norman F. Oblon

Attorney of Record

Registration No. 24,618

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

22850 James J. Kelly, Ph.D.

Registration No. 41,504

(703) 413-3000 (phone) (703) 413-2220 (fax)

United States Patent and Trademark Office

Contents signer for Patents, Box PCI United States Patent and Trademark Office Washington, D.C. 2023

U.S. APPLICATION NUMBER OF FIRST NAMED APPLICANT ATTY. DOCKET NO.

10/030,271 Osamu Noda 217860US

INTERNATIONAL APPLICATION NO.

PCT/JP00/04516

OBLON SPIVAK MCCLELLAND ARE NEUSTADT PC
FOURTH FLOOR

1.A. FILING DATE PRIORITY DATE

7/06/2000 07/08/1999

FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

CONFIRMATION NO. 9016 371 FORMALITIES LETTER

DD/ Seg. List-/Add. Cl. Fe

Date Mailed: 03/28/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- English Translation of the IA
- Preliminary Amendments
- Request for Immediate Examination

RECEIVED

APR 0 3 2002

OBLON, SPIVAK, McCLELLAND, MAJER & NEUSTADT, R.C.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

 Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Additionally the following defects have been observed:



- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - Additional claim fees of \$84 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$84 for a Large Entity:

- Total additional claim fee(s) for this application is \$84
 - \$84 for 2 independent claims over 3.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

KAREN M WILLIAMS

Telephone: (703) 305-3688

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/030,271	PCT/JP00/04516	217860US

FORM PCT/DO/EO/905 (371 Formalities Notice)